You are here

Duke Abstracts Accepted For Presentation At 2019 GU ASCO Symposium

February 12, 2019
By: Jessica Hyland, Writer

The DCI Center for Prostate & Urologic Cancers has 18 abstracts accepted for presentation at the 2019 Genitourinary Cancers (GU) Symposium of the American Society of Clinical Oncology (ASCO) taking place Thursday, Feb. 14 through Saturday, Feb. 16 in San Francisco, California.

Held annually, researchers throughout the world gather for a three-day scientific retreat to  share groundbreaking research in genitourinary malignancies. Over the course of the symposium, attendees will engage in educational sessions, keynote lectures, oral abstract presentations and poster sessions highlighting the latest, breakthrough science in prostate and urologic cancers.

“We are pleased to showcase our data at this year’s GU ASCO symposium and be a part of the cutting-edge research and paradigm shifts in clinical care for prostate and urologic cancers,” said Daniel George, MD, director of genitourinary oncology at Duke Cancer Institute. “This year, our team contributed to 28 publications selected for presentation overall, and 18 of which we will lead. We are committed to advancing our knowledge and moving science forward, and GU ASCO is a great platform to further research collaborations with peers in academics and private industry.”

DCI Center for Prostate & Urologic Cancers GU ASCO Abstracts:

Prostate Cancer

  •  Abstract 687: Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): ARCHES
    AUTHOR: Andrew J. Armstrong, MD
  •  Abstract 172: Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC)
    AUTHOR: Matthew Tucker, MD
  • Abstract 177: Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC)
    AUTHOR: Andrew J. Armstrong, MD
  •  Abstract 183: The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC)
    AUTHOR: Andrew J. Armstrong, MD
  •  Abstract 253: Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    AUTHOR: Daniel J. George, MD
  • Abstract 29: Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): Stream Trial
    AUTHOR: Andrew J. Armstrong, MD
  •  Abstract 212: Overall Survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide
    AUTHOR: Megan McNamara, MD
  • Abstract 211: Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients
    AUTHOR: Daniel J. George, MD
  • Abstract 317: Regional variations in online education test performance for prostate cancer care
    AUTHOR: Daniel J. George, MD
  • Abstract 281: PEAX: Men with metastatic castrate-resistant prostate cancer (mCRCPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET)
    AUTHOR: Michael R. Harrison, MD
  • Abstract 171: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC)
    AUTHOR: William R. Berry, MD
  • Abstract 273: Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer
    AUTHOR: Wei Phin Tan, MD
  • Abstract 237: Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials
    AUTHOR: Andrew J. Armstrong, MD
  • Abstract TPS328: A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects
    AUTHOR: Andrew J. Armstrong, MD
  • Abstract 186: Clinical Outcomes in Caucasian (C), African‐American (AA) and Asian Men with Metastatic Castration‐Resistant Prostate Cancer (mCRPC)
    Author: Susan Halabi, PhD
  • Abstract 190: Radium-223 treatment patterns in a large real-world population
    AUTHOR: Thomas J. Polascik, MD
  • Abstract 268: Racial disparities in radium-223 treatment in a large real-world population
    AUTHOR: Thomas J. Polascik, MD
  • Abstract TPS684: PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143)
    AUTHOR: Rajan T. Gupta, MD
  • Abstract 33: Multi-institutional analysis of synchronous prostate and rectosigmoid cancers
    AUTHORS: Corbin Jacobs, MD and W. Robert Lee, MD
  • Abstract 185: A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy
    AUTHOR: William R. Berry, MD

Kidney Cancer

  • Abstract 658: Patient perspectives on cytoreductive nephrectomy after CARMENA
    AUTHOR: Daniel J. George, MD
  • Abstract 589: Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC)
    AUTHOR: Matthew Labriola, MD
  • Abstract 577: Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC)
    AUTHOR: Jason Zhu, MD
  • Abstract 607: Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC)
    AUTHOR: Jason Zhu, MD
  • Abstract 564: Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214
    AUTHOR: Michael R. Harrison, MD

Bladder Cancer

  • Abstract 357: Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala)
    AUTHOR: Tian Zhang, MD
  • Abstract 400: Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC)
    AUTHOR: Matthew Labriola, MD
  • Abstract 480: Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor
    AUTHOR: Gregory J. Barton, MD